Last reviewed · How we verify
Salvage Chemotherapy
Salvage chemotherapy refers to a combination chemotherapy regimen administered to patients who have failed or relapsed after initial cancer treatment.
Salvage chemotherapy refers to a combination chemotherapy regimen administered to patients who have failed or relapsed after initial cancer treatment. Used for Relapsed or refractory hematologic malignancies, Chemotherapy-resistant solid tumors.
At a glance
| Generic name | Salvage Chemotherapy |
|---|---|
| Also known as | cytarabine, azacytidine, fludarabine, homoharringtonine, aclarubicin, second line chemotherapy, Standard of Care |
| Sponsor | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Salvage chemotherapy is a treatment strategy rather than a single drug entity, typically employing cytotoxic agents to target rapidly dividing cancer cells in patients with chemotherapy-resistant or relapsed disease. The specific mechanism depends on the chemotherapy agents used in the regimen, which may include alkylating agents, platinum compounds, or other cytotoxic drugs designed to overcome prior treatment resistance.
Approved indications
- Relapsed or refractory hematologic malignancies
- Chemotherapy-resistant solid tumors
Common side effects
- Myelosuppression
- Nausea and vomiting
- Mucositis
- Infection
- Alopecia
Key clinical trials
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 (PHASE3)
- Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer (PHASE2)
- The STEP-MIED Trial: Digital Stepped-Care for Emotional Disorders (NA)
- Upfront Neck Dissection Before Radiotherapy in Stage N3 Nasopharyngeal Carcinoma: A Retrospective Study
- Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy (PHASE2)
- A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia (PHASE2)
- Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Salvage Chemotherapy CI brief — competitive landscape report
- Salvage Chemotherapy updates RSS · CI watch RSS
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. portfolio CI